Skip to Content

Amgen Inc AMGN Stock Quote

| Rating as of


Last close prices updated as of Feb 07, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 244
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 241.42  –  244.94
  • Year Range 214.39  –  296.67
  • Market Cap 130.2960 Bil
  • Volume / Avg 2.4 Mil /  2.8 Mil
  • Price / Sales 5.01
  • Price / Book 35.59
  • Forward Div Yield 3.49%
  • Trailing Div Yield 4.05%

Morningstar‘s Stock Analysis AMGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Maintaining Our Amgen FVE Following In-Line Q4; Horizon Acquisition and Pipeline Key to Growth

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

We’re maintaining our $255 fair value estimate for Amgen following fourth-quarter results that showed solid cost controls but significant continued pricing pressure on several of the firm’s franchises. We think the pending Horizon Therapeutics acquisition will boost Amgen’s immunology business at a time when the firm’s pricing power is fading for several of its key branded and biosimilar products. Between in-house pipeline progress and acquired products, we think Amgen is positioned to maintain a solid, diversified portfolio in the long run, warranting a wide moat rating. That said, we’re still waiting for data for key pipeline products in cardiometabolic disease and Horizon’s thyroid eye disease drug Tepezza before assuming Amgen can avoid a slight dip into negative growth territory when Prolia faces biosimilar competition (likely in 2025).

Unlock Our Full Analysis With Morningstar Investor

Key Statistics AMGN

Company Profile AMGN

Business Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

One Amgen Center Drive
Thousand Oaks, CA, 91320-1799
Industry Drug Manufacturers - General
Employees 24,200

Related Articles AMGN

FAQs for Amgen Inc Stock

Yes. AMGN has a forward dividend yield of 3.49%. See AMGN’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

AMGN’s market cap is 130.30 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

AMGN’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

AMGN’s price/sales is 5.01.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

AMGN’s price/forward earnings is 13.55.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

AMGN’s price/book is 35.59.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See AMGN’s valuation ratios compared to the Market Index.

AMGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare AMGN’s historical performance against its industry peers and the overall market.